These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30975567)

  • 1. An ODE-based mixed modelling approach for B- and T-cell dynamics induced by Varicella-Zoster Virus vaccines in adults shows higher T-cell proliferation with Shingrix than with Varilrix.
    Keersmaekers N; Ogunjimi B; Van Damme P; Beutels P; Hens N
    Vaccine; 2019 May; 37(19):2537-2553. PubMed ID: 30975567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling antibody dynamics following herpes zoster indicates that higher varicella-zoster virus viremia generates more VZV-specific antibodies.
    Besbassi H; Garcia-Fogeda I; Quinlivan M; Breuer J; Abrams S; Hens N; Ogunjimi B; Beutels P
    Front Immunol; 2023; 14():1104605. PubMed ID: 36875105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Characterization of CD4
    Voic H; de Vries RD; Sidney J; Rubiro P; Moore E; Phillips E; Mallal S; Schwan B; Weiskopf D; Sette A; Grifoni A
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
    Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
    Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults.
    Schwarz TF; Volpe S; Catteau G; Chlibek R; David MP; Richardus JH; Lal H; Oostvogels L; Pauksens K; Ravault S; Rombo L; Sonder G; Smetana J; Heineman T; Bastidas A
    Hum Vaccin Immunother; 2018 Jun; 14(6):1370-1377. PubMed ID: 29461919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-Dependent Pre-Vaccination Immunity Affects the Immunogenicity of Varicella Zoster Vaccination in Middle-aged Adults.
    van der Heiden M; de Rond LGH; van Zelm MC; Berbers GAM; Boots AMH; Buisman AM
    Front Immunol; 2018; 9():46. PubMed ID: 29410671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.
    Weinberg A; Pang L; Johnson MJ; Caldas Y; Cho A; Tovar-Salazar A; Canniff J; Schmader KE; Popmihajlov Z; Levin MJ
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31092579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
    Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
    Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.
    Godeaux O; Kovac M; Shu D; Grupping K; Campora L; Douha M; Heineman TC; Lal H
    Hum Vaccin Immunother; 2017 May; 13(5):1051-1058. PubMed ID: 28068212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.
    Dagnew AF; Ilhan O; Lee WS; Woszczyk D; Kwak JY; Bowcock S; Sohn SK; Rodriguez Macías G; Chiou TJ; Quiel D; Aoun M; Navarro Matilla MB; de la Serna J; Milliken S; Murphy J; McNeil SA; Salaun B; Di Paolo E; Campora L; López-Fauqued M; El Idrissi M; Schuind A; Heineman TC; Van den Steen P; Oostvogels L;
    Lancet Infect Dis; 2019 Sep; 19(9):988-1000. PubMed ID: 31399377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
    Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P
    Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case of Gianotti-Crosti syndrome following varicella zoster virus vaccination.
    Shibata T; Yanagishita T; Oshima Y; Watanabe D
    J Dermatol; 2019 Jan; 46(1):e36-e38. PubMed ID: 29897138
    [No Abstract]   [Full Text] [Related]  

  • 13. A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus.
    Bharucha T; Ming D; Breuer J
    Hum Vaccin Immunother; 2017 Aug; 13(8):1789-1797. PubMed ID: 28426274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Recombinant Herpes Zoster Vaccine for Primary Immunization of Varicella-seronegative Transplant Recipients.
    L'Huillier AG; Hirzel C; Ferreira VH; Ierullo M; Ku T; Selzner N; Schiff J; Juvet S; Miao C; Schmid DS; Humar A; Kumar D
    Transplantation; 2021 Oct; 105(10):2316-2323. PubMed ID: 33528118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age.
    Chlibek R; Bayas JM; Collins H; de la Pinta ML; Ledent E; Mols JF; Heineman TC
    J Infect Dis; 2013 Dec; 208(12):1953-61. PubMed ID: 23904292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older.
    Cunningham AL; Heineman TC; Lal H; Godeaux O; Chlibek R; Hwang SJ; McElhaney JE; Vesikari T; Andrews C; Choi WS; Esen M; Ikematsu H; Choma MK; Pauksens K; Ravault S; Salaun B; Schwarz TF; Smetana J; Abeele CV; Van den Steen P; Vastiau I; Weckx LY; Levin MJ;
    J Infect Dis; 2018 May; 217(11):1750-1760. PubMed ID: 29529222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): a phase-I, open-label study in Japanese adults.
    Lal H; Zahaf T; Heineman TC
    Hum Vaccin Immunother; 2013 Jul; 9(7):1425-9. PubMed ID: 23584252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Varicella-zoster virus-specific cell-mediated immunity by interferon-γ Enzyme-Linked Immunosorbent Assay in adults ≥50 years of age administered a herpes zoster vaccine.
    Yang P; Chen Z; Zhang J; Li W; Zhu C; Qiu P; Quan Y; Cui X; Yuan L; Jiang C
    J Med Virol; 2019 May; 91(5):829-835. PubMed ID: 30613990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.
    Schwarz TF; Aggarwal N; Moeckesch B; Schenkenberger I; Claeys C; Douha M; Godeaux O; Grupping K; Heineman TC; Fauqued ML; Oostvogels L; Van den Steen P; Lal H
    J Infect Dis; 2017 Dec; 216(11):1352-1361. PubMed ID: 29029224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
    Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
    J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.